Clay minerals-based drug delivery systems for anti-tuberculosis drugs

Saadat, Saeida; Rawtani, Deepak; Parikh, Garvita

doi:10.1016/j.jddst.2022.103755

Cited by 10 publications

(9 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 A novel host-directed therapy for multidrug-resistant tuberculosis was examined. 50 Moxifloxacin and amikacin were incorporated into PLGA NPs via an encapsulation process. Two nanocomposites, alginate-entrapped PLGA NPs and alginatecoated PLGA NPs were produced using a water-oil-water emulsion method, as depicted in Fig.…”

Section: Review Materials Advancesmentioning

confidence: 99%

Advances in the fabrication of potential nanomaterials for diagnosis and effective treatment of tuberculosis

El-Shabasy,

Zahran,

Ibrahim

et al. 2024

Mater. Adv.

View full text Add to dashboard Cite

show abstract

Section: Review Materials Advancesmentioning

confidence: 99%

Advances in the fabrication of potential nanomaterials for diagnosis and effective treatment of tuberculosis

El-Shabasy,

Zahran,

Ibrahim

et al. 2024

Mater. Adv.

View full text Add to dashboard Cite

show abstract

“…However, this release profile is a challenge when modulating the dissolution of widely soluble drugs carried by hydrophilic polymers is necessary. Therefore, adding palygorskite enables slower drug dissolution [ 21 ] and provides adsorbent properties that favor the physicochemical stability of systems involving drugs and/or hygroscopic matrices [ 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Biocomposite for Prolonged Release of Water-Soluble Drugs

et al. 2023

View full text Add to dashboard Cite

This study aimed to develop a prolonged-release system based on palygorskite and chitosan, which are natural ingredients widely available, affordable, and accessible. The chosen model drug was ethambutol (ETB), a tuberculostatic drug with high aqueous solubility and hygroscopicity, which is incompatible with other drugs used in tuberculosis therapy. The composites loaded with ETB were obtained using different proportions of palygorskite and chitosan through the spray drying technique. The main physicochemical properties of the microparticles were determined using XRD, FTIR, thermal analysis, and SEM. Additionally, the release profile and biocompatibility of the microparticles were evaluated. As a result, the chitosan–palygorskite composites loaded with the model drug appeared as spherical microparticles. The drug underwent amorphization within the microparticles, with an encapsulation efficiency greater than 84%. Furthermore, the microparticles exhibited prolonged release, particularly after the addition of palygorskite. They demonstrated biocompatibility in an in vitro model, and their release profile was influenced by the proportion of inputs in the formulation. Therefore, incorporating ETB into this system offers improved stability for the administered product in the initial tuberculosis pharmacotherapy dose, minimizing its contact with other tuberculostatic agents in the treatment, as well as reducing its hygroscopicity.

show abstract

“…Systems based on clay–drug nanohybrids have been widely reported in the literature, presenting interesting characteristics that have increased the bioavailability of several biomolecules, such as increased solubility of hydrophobic drugs, protection against degradation along the gastrointestinal tract, controlled release, and being pH responsive [ 20 , 31 , 32 , 33 ]. These systems are obtained through the establishment of interactions between the active sites of the nanocarrier and the functional groups present in the drug molecule.…”

Section: Introductionmentioning

confidence: 99%

“…These systems are obtained through the establishment of interactions between the active sites of the nanocarrier and the functional groups present in the drug molecule. They can be prepared using several different methods, including: encapsulation, immobilization, ion exchange, and electrostatic interactions [ 33 ]. We have previously described how to obtain this type of system for the drugs isoniazid and rifampicin using the clay mineral palygorskite [ 4 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic

et al. 2023

View full text Add to dashboard Cite

The present work describes the development of a hybrid and pH-responsive system for rifampicin using the clay mineral ‘montmorillonite’ as a nanocarrier. The influence of operational variables on the drug incorporation process was evaluated using 24 factorial designs. Under optimized conditions, the experiment allowed an incorporated drug dose equivalent to 98.60 ± 1.21 mg/g. Hybrid systems were characterized by different characterization techniques (FTIR, XRD, TGA, DSC, and SEM) to elucidate the mechanism of interaction between the compounds used. Through in vitro release studies, it was possible to verify the efficacy of the pH-dependent system obtained, with approximately 70% of the drug released after sixteen hours in simulated intestinal fluid. The adjustment of the experimental release data to the theoretical model of Higuchi and Korsmeyer–Peppas indicated that the release of rifampicin occurs in a prolonged form from montmorillonite. Elucidation of the interactions between the drug and this raw clay reinforces its viability as a novel carrier to develop an anti-TB/clay hybrid system with good physical and chemical stability.

show abstract

Clay minerals-based drug delivery systems for anti-tuberculosis drugs

Cited by 10 publications

References 65 publications

Advances in the fabrication of potential nanomaterials for diagnosis and effective treatment of tuberculosis

Advances in the fabrication of potential nanomaterials for diagnosis and effective treatment of tuberculosis

Biocomposite for Prolonged Release of Water-Soluble Drugs

Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic

Contact Info

Product

Resources

About